Shandong Pharmaceutical Glass (600529) Fundamentals 2026 — P/E 18.8x, Revenue Analysis | SniperIQ
Shandong Pharmaceutical Glass (600529) is a CN-listed Consumer Cyclical company in Packaging & Containers with a market capitalization of ¥12.5B, trading at ¥18.80 on the SHH. This SniperIQ fundamentals page covers Shandong Pharmaceutical Glass's valuation (P/E 18.8x, P/B 1.5x), profitability (net margin 15.0%), revenue (¥4.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shandong Pharmaceutical Glass's market cap?
Shandong Pharmaceutical Glass (600529) has a market capitalization of approximately ¥12.5B, trading at ¥18.80 on the SHH. Market cap moves with the live share price.
What is Shandong Pharmaceutical Glass's P/E ratio?
Shandong Pharmaceutical Glass's trailing twelve-month P/E ratio is 18.8x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Consumer Cyclical sector peers rather than read in isolation.
How profitable is Shandong Pharmaceutical Glass?
Shandong Pharmaceutical Glass runs a net profit margin of 15.0%, a gross margin of 32.9%, and an operating margin of 17.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shandong Pharmaceutical Glass generate?
Shandong Pharmaceutical Glass reported revenue of ¥4.5B for fiscal year 2025, with net income of ¥690M and earnings per share (EPS) of 1.04. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shandong Pharmaceutical Glass pay a dividend?
Shandong Pharmaceutical Glass offers a trailing dividend yield of about 2.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shandong Pharmaceutical Glass financially healthy?
Shandong Pharmaceutical Glass carries a debt-to-equity ratio of 0.07x and a current ratio of 3.79x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shandong Pharmaceutical Glass a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shandong Pharmaceutical Glass (600529) the key facts are: market cap ¥12.5B, P/E 18.8x, revenue ¥4.5B, 52-week range 17.3-23.99. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Cyclical peers and form your own view.
Track Shandong Pharmaceutical Glass's full fundamentals live
Get Shandong Pharmaceutical Glass's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.